Pharmaceutical composition for external use

The minoxidil-containing composition addresses blending and spreading issues by incorporating specific compounds and additives, improving skin compatibility and user experience.

JP2024166362AActive Publication Date: 2024-11-28TAISHO PHARMACEUTICAL CO LTD
View PDF 10 Cites 0 Cited by

Patent Information

Application Number
JP2024161100
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2020-04-08
Filing Date
2024-09-18
Publication Date
2024-11-28
Estimated Expiration
2040-10-13

AI Technical Summary

Technical Problem

Existing minoxidil-containing formulations have difficulty blending and spreading on the scalp due to surface free energy effects with hydrophobic skin, and high concentrations of minoxidil worsen the feeling of application.

Method used

A minoxidil-containing external pharmaceutical composition comprising minoxidil, crotamiton, ethyl aminobenzoate, urea, cetylpyridinium, or benzethonium, along with water, lower alcohols, polyhydric alcohols, and pH adjusters, to enhance skin compatibility and spreading.

Benefits of technology

The composition improves skin blending and spreading of minoxidil, maintaining effective hair growth benefits while enhancing user comfort.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024166362000001
    Figure 2024166362000001
  • Figure 2024166362000002
    Figure 2024166362000002
  • Figure 2024166362000003
    Figure 2024166362000003
Patent Text Reader

Abstract

To provide a minoxidil-containing pharmaceutical composition for external use, since there is a need for a minoxidil-containing preparation to agree with the surface of scalp and spread so that the minoxidil in the minoxidil-containing preparation is efficiently absorbed from the scalp.SOLUTION: A pharmaceutical composition for external use contains (a) minoxidil, (b) at least one selected from the group consisting of urea, cetylpyridinium and a salt thereof, ethyl aminobenzoate, crotamiton and benzethonium and a salt thereof and (c) water. The inventive composition is suitable as liquid chemical, lotion or tonic.SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to a pharmaceutical composition for external use containing minoxidil. [Background technology]

[0002] Minoxidil, whose chemical name is 6-(1-piperidinyl)-2,4-pyrimidinediamine-3-oxide, is known for its application as a hair restorer (Patent Document 1), and there are many reports of it being a drug that exhibits excellent hair growth and hair regrowth effects. The basic performance required for a hair restorer containing minoxidil is excellent absorption of minoxidil from the scalp (Patent Document 2).

[0003] In order for minoxidil in a formulation containing minoxidil to be efficiently absorbed from the scalp, it is important that the formulation containing minoxidil blends with and spreads on the surface of the scalp. However, a formulation containing a large amount of water maintains a droplet state and does not easily spread on the skin surface due to the surface free energy acting between the formulation and the hydrophobic skin. As a technique for improving skin blending, for example, a method using polyether-modified silicone or polyglycerin-modified silicone, and sucrose fatty acid ester has been proposed (Patent Document 3). In addition, Patent Document 4 shows that the feeling of the formulation spreading on the scalp worsens as the concentration of minoxidil increases.

[0004] However, none of the above Patent Documents 1 to 4 contain any description that suggests the use of the configuration of the present invention in order to obtain the present invention, which is a minoxidil-containing pharmaceutical composition for external use that is compatible with the skin. [Prior art documents] [Patent documents]

[0005] [Patent Document 1] U.S. Pat. No. 4,139,619 [Patent Document 2] Japanese Patent Application Publication No. 11-349451 [Patent Document 3] JP 2016-84323 A [Patent Document 4] JP 2019-142851 A Summary of the Invention [Problem to be solved by the invention]

[0006] The present invention aims to provide a minoxidil-containing pharmaceutical composition for external use that is compatible with the skin. [Means for solving the problem]

[0007] In order to solve the above problems, the present invention provides an external pharmaceutical composition containing (a) minoxidil, (b) at least one member selected from the group consisting of crotamiton, ethyl aminobenzoate, urea, cetylpyridinium and / or a salt thereof, and benzethonium and / or a salt thereof, and (c) water.

[0008] That is, the present invention provides: (1) A pharmaceutical composition for external application, comprising (a) minoxidil, (b) at least one member selected from the group consisting of urea, cetylpyridinium and its salts, ethyl aminobenzoate, crotamiton, and benzethonium and its salts, and (c) water; (2) The pharmaceutical composition for external application according to (1), wherein the component (b) is urea. (3) The pharmaceutical composition for external application according to (1), wherein the component (b) is cetylpyridinium and / or a salt thereof. (4) The pharmaceutical composition for external application according to (1), wherein the component (b) is ethyl aminobenzoate. (5) The pharmaceutical composition for external application according to (1), wherein the component (b) is crotamiton. (6) The pharmaceutical composition for external application according to (1), wherein the component (b) is benzethonium and / or a salt thereof. (7) (a) The pharmaceutical composition for external application according to (1), wherein the content of minoxidil is 3 to 15 w / v %. (8) The pharmaceutical composition for external application according to any one of (1) to (7), further comprising a lower alcohol. (9) The pharmaceutical composition for external application according to any one of (1) to (8), further comprising a polyhydric alcohol. (10) The pharmaceutical composition for external application according to any one of (1) to (9), further comprising a pH adjuster. (11) The composition for external use according to (8), wherein the lower alcohol is a lower alcohol having 1 to 5 carbon atoms. (12) The pharmaceutical composition for external application according to (9), wherein the polyhydric alcohol is at least one selected from the group consisting of 1,3-butylene glycol, dipropylene glycol, propylene glycol, glycerin, and polyethylene glycol. (13) The pharmaceutical composition for external application according to (10), wherein the pH adjuster is at least one selected from the group consisting of citric acid, malic acid, lactic acid, tartaric acid, phosphoric acid, hydrochloric acid, and sulfuric acid. (14) The pharmaceutical composition for external application according to (1), wherein the water content is 5 to 75 w / w%. (15) The pharmaceutical composition for external application according to any one of (1) to (14), which has a dosage form of a liquid, a lotion, or a tonic. It is. Effect of the Invention

[0009] The present invention makes it possible to provide a minoxidil-containing topical pharmaceutical composition that is highly compatible with the skin by containing (a) minoxidil, (b) at least one member selected from the group consisting of crotamiton, ethyl aminobenzoate, urea, cetylpyridinium and / or a salt thereof, and benzethonium and / or a salt thereof, and (c) water. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0010] The minoxidil used in the topical pharmaceutical composition of the present invention may be of a quality that is generally used in pharmaceuticals. The content of minoxidil used in the present invention is preferably 1 to 15 w / v% based on the total content of the topical pharmaceutical composition. In the topical pharmaceutical composition of the present invention, the higher the content of minoxidil, the greater the problem of skin compatibility. Therefore, the higher the concentration of minoxidil in the topical pharmaceutical composition, the greater the significance of carrying out the present invention. Specifically, the content of minoxidil in the topical pharmaceutical composition of the present invention is more preferably 3 w / v% or more, more preferably 5 w / v% or more, and the upper limit is more preferably 15 w / v% or less, more preferably 10 w / v% or less.

[0011] The crotamiton used in the present invention may be of a quality generally used in pharmaceuticals. In terms of the effects of the present invention, the content of crotamiton in the pharmaceutical composition for external use of the present invention is preferably 0.01 to 10 w / v%, more preferably 0.1 to 5 w / v%.

[0012] The ethyl aminobenzoate of the present invention is sometimes called benzocaine, and those of the quality generally used in pharmaceuticals can be used appropriately. In the present invention, the content of ethyl aminobenzoate in the pharmaceutical composition for external use of the present invention is preferably 0.01 to 10 w / v%, more preferably 0.1 to 5 w / v%, from the viewpoint of the effect of the present invention.

[0013] The urea of ​​the present invention may be of a quality generally used in pharmaceuticals. In terms of the effects of the present invention, the content of urea in the pharmaceutical composition for external use of the present invention is preferably 0.01 to 10 w / v%, more preferably 0.1 to 5 w / v%.

[0014] Examples of the cetylpyridinium and / or its salt of the present invention include cetylpyridinium and cetylpyridinium chloride. These can be appropriately used in the quality of ordinary pharmaceuticals. In the present invention, the content of cetylpyridinium and / or its salt in the external pharmaceutical composition of the present invention is preferably 0.01-2 w / v%, more preferably 0.04-1 w / v%, from the viewpoint of the effect of the present invention.

[0015] The benzethonium and / or its salt of the present invention may be, for example, benzethonium chloride. These may be of the quality generally used in pharmaceuticals. In the present invention, the content of benzethonium and / or its salt in the pharmaceutical composition for external use of the present invention is preferably 0.01-5 w / v%, more preferably 0.02-0.5 w / v%, from the viewpoint of the effect of the present invention.

[0016] In terms of the effects of the present invention, the water content in the pharmaceutical composition for external use of the present invention is preferably 1 to 75 w / w%, more preferably 5 to 50 w / w%, even more preferably 8 to 30 w / w%, and most preferably 12 to 30 w / w%. The water content in the pharmaceutical composition for external use of the present invention can be measured by the Karl Fischer method.

[0017] The pharmaceutical composition for external application of the present invention may contain a pH adjuster as necessary. Examples of the pH adjuster include organic acids such as citric acid, malic acid, lactic acid, and tartaric acid, and inorganic acids such as phosphoric acid, hydrochloric acid, and sulfuric acid. The pH of the pharmaceutical composition for external application of the present invention is preferably adjusted to 5 to 8, more preferably 5.5 to 7.5, and most preferably 6 to 7.

[0018] The pharmaceutical composition for external use of the present invention may contain a lower alcohol if necessary. Examples of lower alcohols include those having 1 to 5 carbon atoms, such as ethanol and isopropanol, and these may be used in combination. The content of the lower alcohol in the pharmaceutical composition for external use of the present invention is not particularly limited in the present invention, and the required amount may be determined by appropriate preparation. For example, the content is preferably 20 w / v% or more in the total composition, more preferably 30 w / v% or more, even more preferably 35 w / v% or more, and even more preferably 50 w / v% or more. The upper limit is more preferably 80 w / v% or less, and even more preferably 70 w / v% or less.

[0019] The topical pharmaceutical composition of the present invention may contain a polyhydric alcohol as necessary. Examples of polyhydric alcohols include 1,3-butylene glycol, dipropylene glycol, propylene glycol, glycerin, polyethylene glycol, etc., and these may be used alone or in combination of two or more. The content of the polyhydric alcohol is not particularly limited in the present invention, and the required amount may be determined by appropriate preparation. For example, the content of the polyhydric alcohol in the topical pharmaceutical composition of the present invention is preferably 5 w / v% or more, more preferably 10 w / v% or more, and the upper limit is preferably 30 w / v% or less, taking into consideration the feeling of use such as less stickiness.

[0020] In addition to the above-mentioned components, the pharmaceutical composition for external use of the present invention may contain necessary active ingredients and auxiliary ingredients within the range that does not impair the effects of the present invention. Examples of medicinal ingredients that are preferably added or blended into the pharmaceutical composition for external use of the present invention include ingredients selected from the group consisting of menthol, vitamin E acetate, hinokitiol, pyridoxine hydrochloride, glycyrrhetinic acid, and diphenhydramine hydrochloride. The amount of these ingredients to be added is not particularly limited, and can be determined experimentally while taking into consideration the feeling of use, the stability of minoxidil, the composition of the solvent system, etc.

[0021] In the topical pharmaceutical composition of the present invention, in addition to the above-mentioned ingredients, various active ingredients and auxiliary ingredients used in general topical preparations can be blended within the range that does not impair the effects of the present invention. For example, excipients, hair growth ingredients (6-benzylaminopurine, adenosine, pentadecanoic acid glyceride, Polygonum polymorpha, etc.), vasodilators (carpronium chloride, benzyl nicotinate, Swertia japonica extract, Panax ginseng extract, Panax ginseng tincture, Capsicum anguicum tincture, etc.), antihistamines (isothipendyl hydrochloride, etc.), anti-inflammatory agents (guaiazulene, etc.), keratolytic agents (salicylic acid, etc.), bactericides (chlorhexidine gluconate, isopropylmethylphenol, quaternary ammonium salts, piroctone olamine, etc.), moisturizers (hyaluronic acid or its salts, chondroitin sulfate, etc.), various plants and animals (yew, moutan pi, licorice, Hypericum perforatum, aconite, loquat, artemisonia japonica, comfrey, angelica tree, saxifraga, etc.), It is possible to blend in commonly used ingredients such as extracts of flan, Sanshishi, rosemary, sage, Saussurea japonica, Seimokko, hops, placenta, saw palmetto, pumpkin seed, etc., vitamins (ascorbic acid, thiamine nitrate, cyanocobalamin, biotin, etc.), antioxidants (dibutylhydroxytoluene, sodium pyrosulfite, tocopherol, sodium edetate, ascorbic acid, isopropyl gallate, etc.), solubilizers (diisopropyl adipate, isopropyl myristate, various vegetable oils, various animal oils, alkyl glyceryl ethers, hydrocarbons, etc.), metabolic activators, gelling agents (water-soluble polymers, etc.), adhesives, fragrances, refreshing agents (peppermint oil, camphor, etc.), dyes, etc.

[0022] Furthermore, the topical pharmaceutical composition of the present invention is preferably in a liquid dosage form, and can be made into a suitable topical pharmaceutical composition such as a solution, lotion, tonic, or the like.

[0023] The pharmaceutical composition for external application of the present invention can be prepared by incorporating the above-mentioned components in a conventional manner.

[0024] The thus obtained pharmaceutical composition for external application of the present invention can be used as a preparation for application to the skin, such as an agent for hair, eyelashes, eyebrows, etc.

[0025] The present invention will be explained in more detail below with reference to examples, comparative examples, and test examples, but the present invention is not limited by these examples, etc. The moisture contents in the examples and comparative examples were measured using a Karl Fischer moisture meter. EXAMPLES

[0026] Example 1 5 g of minoxidil, 1 g of crotamiton, 10 g of 1,3-butylene glycol, 60 g of ethanol, an appropriate amount of phosphoric acid, and purified water were added to make a total volume of 100 mL, and the mixture was stirred and dissolved to obtain a pharmaceutical composition for external use with a pH of 6.17.

[0027] Example 2 5 g of minoxidil, 1 g of ethyl aminobenzoate, 10 g of 1,3-butylene glycol, 60 g of ethanol, an appropriate amount of phosphoric acid, and purified water were added to make a total volume of 100 mL, and the mixture was stirred and dissolved to obtain a pharmaceutical composition for external use with a pH of 6.17.

[0028] Example 3 5 g of minoxidil, 1 g of urea, 10 g of 1,3-butylene glycol, 60 g of ethanol, an appropriate amount of phosphoric acid, and purified water were added to make a total volume of 100 mL, and the mixture was stirred and dissolved to obtain a pharmaceutical composition for external use with a pH of 6.19.

[0029] Example 4 5 g of minoxidil, 0.2 g of cetylpyridinium chloride hydrate, 10 g of 1,3-butylene glycol, 60 g of ethanol, an appropriate amount of phosphoric acid, and purified water were added to make a total volume of 100 mL, and the mixture was stirred and dissolved to obtain a pharmaceutical composition for external use with a pH of 6.12.

[0030] Example 5 5 g of minoxidil, 0.5 g of benzethonium chloride, 10 g of 1,3-butylene glycol, 60 g of ethanol, an appropriate amount of phosphoric acid, and purified water were added to make a total volume of 100 mL, and the mixture was stirred and dissolved to obtain a pharmaceutical composition for external use with a pH of 6.10.

[0031] Comparative Example 1 5 g of minoxidil, 10 g of 1,3-butylene glycol, 60 g of ethanol, an appropriate amount of phosphoric acid, and purified water were added to make a total volume of 100 mL, and the mixture was stirred and dissolved to obtain a pharmaceutical composition for external use with a pH of 6.16.

[0032] Comparative Example 2 5 g of minoxidil, 1 g of panthenol, 10 g of 1,3-butylene glycol, 60 g of ethanol, an appropriate amount of phosphoric acid, and purified water were added to make a total volume of 100 mL, and the mixture was stirred and dissolved to obtain a pharmaceutical composition for external use with a pH of 6.15.

[0033] Table 1 shows the formulations and pH after preparation of Examples 1 to 5 and Comparative Examples 1 and 2.

[0034] [Table 1]

[0035] (Skin compatibility evaluation) 100 μL of each test liquid from Examples 1 to 5 and Comparative Examples 1 and 2 was measured using a micropipette (manufactured by Eppendorf) and dropped onto a Bioskin plate (#40, manufactured by Beaulax). 30 seconds after dropping, the major axis and minor axis of the spread liquid were measured, and the multiplied value was used as a skin compatibility score. The skin compatibility improvement rate was calculated according to the following [Equation 1]. The calculated results are shown in Table 2.

[0036] [Formula 1] Skin compatibility improvement rate (%) = (skin compatibility score of each test liquid / skin compatibility score of Comparative Example 1) x 100

[0037] [Table 2]

[0038] As shown in Table 2, the topical pharmaceutical compositions of Examples 1 to 5 of the present invention had improved compatibility with the skin compared to the topical pharmaceutical composition of Comparative Example 1 which did not contain the component (b).

[0039] Example 6 Minoxidil (5 g), crotamiton (1 g), 1,3-butylene glycol (14 g), propylene glycol (15 g), purified water (12 g), a suitable amount of tartaric acid, and ethanol were added to make a total volume of 100 mL, and the mixture was stirred and dissolved to obtain a pharmaceutical composition for external use with a pH of 6.75.

[0040] Example 7 5 g of minoxidil, 1 g of ethyl aminobenzoate, 14 g of 1,3-butylene glycol, 15 g of propylene glycol, 12 g of purified water, an appropriate amount of tartaric acid, and ethanol were added to make a total volume of 100 mL, and the mixture was stirred and dissolved to obtain a pharmaceutical composition for external use with a pH of 6.76.

[0041] Example 8 Minoxidil (5 g), urea (1 g), 1,3-butylene glycol (14 g), propylene glycol (15 g), purified water (12 g), a suitable amount of tartaric acid, and ethanol (to a total volume of 100 mL) were added, and the mixture was stirred and dissolved to obtain a pharmaceutical composition for external use with a pH of 6.77.

[0042] Example 9 5 g of minoxidil, 0.2 g of cetylpyridinium chloride hydrate, 14 g of 1,3-butylene glycol, 15 g of propylene glycol, 12 g of purified water, an appropriate amount of tartaric acid, and ethanol were added to make a total volume of 100 mL, and the mixture was stirred and dissolved to obtain a pharmaceutical composition for external use with a pH of 6.70.

[0043] Example 10 Minoxidil 5 g, benzethonium chloride 0.5 g, 1,3-butylene glycol 14 g, propylene glycol 15 g, purified water 12 g, a suitable amount of tartaric acid, and ethanol were added to make a total volume of 100 mL, and the mixture was stirred and dissolved to obtain a pharmaceutical composition for external use with a pH of 6.67.

[0044] Comparative Example 3 5 g of minoxidil, 14 g of 1,3-butylene glycol, 15 g of propylene glycol, 12 g of purified water, an appropriate amount of tartaric acid, and ethanol were added to make a total volume of 100 mL, and the mixture was stirred and dissolved to obtain a pharmaceutical composition for external use with a pH of 6.77.

[0045] Comparative Example 4 5 g of minoxidil, 1 g of panthenol, 14 g of 1,3-butylene glycol, 15 g of propylene glycol, 12 g of purified water, an appropriate amount of tartaric acid, and ethanol were added to make a total volume of 100 mL, and the mixture was stirred and dissolved to obtain a pharmaceutical composition for external use with a pH of 6.75.

[0046] Table 3 shows the formulations and pH after preparation of Examples 6 to 10 and Comparative Examples 3 and 4.

[0047] [Table 3]

[0048] (Skin compatibility evaluation) 100 μL of each test liquid from Examples 6 to 10 and Comparative Examples 3 to 4 was measured using a micropipette (manufactured by Eppendorf) and dropped onto a Bioskin plate (#40, manufactured by Bealux). 30 seconds after dropping, the major and minor axes of the spread liquid were measured, and the multiplied value was used as a skin compatibility score. The skin compatibility improvement rate was calculated according to the following [Equation 2]. The calculated results are shown in Table 4.

[0049] [Formula 2] Skin compatibility improvement rate (%) = (skin compatibility score of each test liquid / skin compatibility score of Comparative Example 3) x 100

[0050] [Table 4]

[0051] As shown in Table 4, the topical pharmaceutical compositions of Examples 6 to 10 of the present invention had improved compatibility with the skin compared to the topical pharmaceutical composition of Comparative Example 3 which did not contain the component (b).

[0052] Example 11 5 g of minoxidil, 1 g of crotamiton, 1 g of 1,3-butylene glycol, 12 g of glycerin, 55 g of ethanol, an appropriate amount of lactic acid, an appropriate amount of citric acid, and purified water were added to make a total volume of 100 mL, and the mixture was stirred and dissolved to obtain a pharmaceutical composition for external use with a pH of 6.93.

[0053] Example 12 5 g of minoxidil, 1 g of ethyl aminobenzoate, 1 g of 1,3-butylene glycol, 12 g of glycerin, 55 g of ethanol, an appropriate amount of lactic acid, an appropriate amount of citric acid, and purified water were added to make a total volume of 100 mL, and the mixture was stirred and dissolved to obtain a pharmaceutical composition for external use with a pH of 6.93.

[0054] (Example 13) 5 g of minoxidil, 1 g of urea, 1 g of 1,3-butylene glycol, 12 g of glycerin, 55 g of ethanol, an appropriate amount of lactic acid, an appropriate amount of citric acid, and purified water were added to make a total volume of 100 mL, and the mixture was stirred and dissolved to obtain a pharmaceutical composition for external use with a pH of 6.94.

[0055] Example 14 5 g of minoxidil, 0.2 g of cetylpyridinium chloride hydrate, 1 g of 1,3-butylene glycol, 12 g of glycerin, 55 g of ethanol, an appropriate amount of lactic acid, an appropriate amount of citric acid, and purified water were added to make a total volume of 100 mL, and the mixture was stirred and dissolved to obtain a pharmaceutical composition for external use with a pH of 6.86.

[0056] Example 15 5 g of minoxidil, 0.5 g of benzethonium chloride, 1 g of 1,3-butylene glycol, 12 g of glycerin, 55 g of ethanol, an appropriate amount of lactic acid, an appropriate amount of citric acid, and purified water were added to make a total volume of 100 mL, and the mixture was stirred and dissolved to obtain a pharmaceutical composition for external use with a pH of 6.85.

[0057] Comparative Example 5 5 g of minoxidil, 1 g of 1,3-butylene glycol, 12 g of glycerin, 55 g of ethanol, an appropriate amount of lactic acid, an appropriate amount of citric acid, and purified water were added to make a total volume of 100 mL, and the mixture was stirred and dissolved to obtain a pharmaceutical composition for external use with a pH of 6.90.

[0058] Comparative Example 6 5 g of minoxidil, 1 g of panthenol, 1 g of 1,3-butylene glycol, 12 g of glycerin, 55 g of ethanol, an appropriate amount of lactic acid, an appropriate amount of citric acid, and purified water were added to make a total volume of 100 mL, and the mixture was stirred and dissolved to obtain a pharmaceutical composition for external use with a pH of 6.91.

[0059] Table 5 shows the formulations and pH after preparation of Examples 11 to 15 and Comparative Examples 5 to 6.

[0060] [Table 5]

[0061] (Skin compatibility evaluation) 100 μL of each test liquid from Examples 11 to 15 and Comparative Examples 5 to 6 was measured using a micropipette (manufactured by Eppendorf) and dropped onto a Bioskin plate (#40, manufactured by Beaulax). 30 seconds after dropping, the major and minor axes of the spread liquid were measured, and the multiplied value was used as a skin compatibility score. The skin compatibility improvement rate was calculated according to the following [Equation 3]. The calculation results are shown in Table 6.

[0062] [Formula 3] Skin compatibility improvement rate (%) = (skin compatibility score of each test liquid / skin compatibility score of Comparative Example 5) x 100

[0063] [Table 6]

[0064] As shown in Table 6, the topical pharmaceutical compositions of Examples 11 to 15 of the present invention had improved compatibility with the skin compared to the topical pharmaceutical composition of Comparative Example 5 which did not contain the component (b).

[0065] (Example 16) Minoxidil (5 g), crotamiton (1 g), 1,3-butylene glycol (10 g), purified water (17 g), an appropriate amount of phosphoric acid, and ethanol (to a total volume of 100 mL) were dissolved by stirring to obtain a pharmaceutical composition for external use with a pH of 6.08.

[0066] (Example 17) 5 g of minoxidil, 1 g of ethyl aminobenzoate, 10 g of 1,3-butylene glycol, 17 g of purified water, an appropriate amount of phosphoric acid, and ethanol were added to make a total volume of 100 mL, and the mixture was stirred and dissolved to obtain a pharmaceutical composition for external use with a pH of 6.09.

[0067] (Example 18) 5 g of minoxidil, 1 g of urea, 10 g of 1,3-butylene glycol, 17 g of purified water, an appropriate amount of phosphoric acid, and ethanol were added to make a total volume of 100 mL, and the mixture was stirred and dissolved to obtain a pharmaceutical composition for external use with a pH of 6.09.

[0068] (Example 19) 5 g of minoxidil, 0.2 g of cetylpyridinium chloride hydrate, 10 g of 1,3-butylene glycol, 17 g of purified water, an appropriate amount of phosphoric acid, and ethanol were added to bring the total volume to 100 mL, and the mixture was stirred and dissolved to obtain a pharmaceutical composition for external use with a pH of 6.04.

[0069] (Example 20) Minoxidil (5 g), benzethonium chloride (0.5 g), 1,3-butylene glycol (10 g), purified water (17 g), an appropriate amount of phosphoric acid, and ethanol were added to make a total volume of 100 mL, and the mixture was stirred and dissolved to obtain a pharmaceutical composition for external use with a pH of 6.02.

[0070] Comparative Example 7 5 g of minoxidil, 10 g of 1,3-butylene glycol, 17 g of purified water, an appropriate amount of phosphoric acid, and ethanol were added to make a total volume of 100 mL, and the mixture was stirred and dissolved to obtain a pharmaceutical composition for external use with a pH of 6.05.

[0071] Comparative Example 8 5 g of minoxidil, 1 g of panthenol, 10 g of 1,3-butylene glycol, 17 g of purified water, an appropriate amount of phosphoric acid, and ethanol were added to make a total volume of 100 mL, and the mixture was stirred and dissolved to obtain a pharmaceutical composition for external use with a pH of 6.08.

[0072] The formulations and pH after preparation of Examples 16 to 20 and Comparative Examples 7 to 8 are shown in Table 7.

[0073] [Table 7]

[0074] (Skin compatibility evaluation) 100 μL of each test liquid from Examples 16 to 20 and Comparative Examples 7 to 8 was measured using a micropipette (manufactured by Eppendorf) and dropped onto a Bioskin plate (#40, manufactured by Beaulax). 30 seconds after dropping, the major and minor axes of the spread liquid were measured, and the multiplied value was used as a skin compatibility score. The skin compatibility improvement rate was calculated according to the following [Equation 4]. The calculation results are shown in Table 8.

[0075] [Formula 4] Skin compatibility improvement rate (%) = (skin compatibility score of each test liquid / skin compatibility score of Comparative Example 7) x 100

[0076] [Table 8]

[0077] As shown in Table 8, the topical pharmaceutical compositions of Examples 16 to 20 of the present invention had improved compatibility with the skin compared to the topical pharmaceutical composition of Comparative Example 7 which did not contain the component (b).

[0078] Another example of a topical composition of the present invention is a composition containing, for example, 0.1 to 10 w / v% minoxidil, and as active ingredients or auxiliary ingredients, 0.1 to 5 w / v% menthol, 0.001 to 1 w / v% vitamin E acetate, 0.001 to 1 w / v% pyridoxine hydrochloride, 0.001 to 1 w / v% hinokitiol, 0.001 to 1 w / v% glycyrrhetinic acid, 0.001 to 1 w / v% diphenhydramine hydrochloride, 0.001 to 1 w / v% pantothenyl ethyl ether or panthenol, 0.1 to 5 w / v% 1,3-butylene Examples of such compositions include those prepared by blending glycol 2-30 w / v%, glycerin 1-30 w / v%, ethanol 20-80 w / v%, antioxidants (dibutylhydroxytoluene, dibutylhydroxyanisole, sodium pyrosulfate, sodium edetate, or propyl gallate) 0.001-1 w / v%, an appropriate amount of phosphoric acid, glycine 0.00001-1 w / v%, L-arginine 0.00001-1 w / v%, ascorbic acid 0.000001-1 w / v%, and the remaining amount is water. These active ingredients and auxiliary ingredients can be blended appropriately taking into consideration the feel of use, the stability of minoxidil, the solvent system composition, etc. An example of a formulation for this topical composition is shown in Table 9.

[0079] [Table 9]

[0080] Another example of a topical composition of the present invention is a composition for topical use that contains, for example, 0.1 to 10 w / v% minoxidil, and as active ingredients or auxiliary ingredients, 0.1 to 5 w / v% menthol, 0.001 to 1 w / v% vitamin E acetate, 0.001 to 1 w / v% pyridoxine hydrochloride, 0.001 to 1 w / v% hinokitiol, 0.001 to 1 w / v% glycyrrhetinic acid, 0.001 to 1 w / v% diphenhydramine hydrochloride, 0.1 to 5 w / v% pantothenyl ethyl ether or panthenol, 1 to 5 w / v% crotamiton, 0.5 to 5 w / v% ethyl aminobenzoate, 1 to 5 w / v% urea, cetiripyridinium and / or its derivatives. 0.04-0.2 w / v% of a salt of minoxidil, 0.05-0.5 w / v% of benzethonium and / or its salt, 2-30 w / v% of 1,3-butylene glycol, 1-30 w / v% of glycerin, 20-70 w / v% of ethanol, 0.001-1 w / v% of an antioxidant (dibutylhydroxytoluene, dibutylhydroxyanisole, sodium pyrosulfate, sodium edetate, or propyl gallate), an appropriate amount of phosphoric acid, 0.00001-1 w / v% of glycine, 0.00001-1 w / v% of L-arginine, and 0.000001-1 w / v% of ascorbic acid, with the remaining amount being water. These active ingredients and auxiliary ingredients can be appropriately blended in consideration of the feeling of use, the stability of minoxidil, the composition of the solvent system, etc. A formulation example of this topical composition is shown in Table 10.

[0081] [Table 10]

Claims

1. A pharmaceutical composition for external application, comprising (a) minoxidil, (b) at least one member selected from the group consisting of urea, cetylpyridinium and its salts, ethyl aminobenzoate, crotamiton, and benzethonium and its salts, and (c) water.

2. The topical pharmaceutical composition according to claim 1, wherein component (b) is urea.

3. The external pharmaceutical composition according to claim 1, wherein component (b) is cetylpyridinium and / or a salt thereof.

4. 2. The topical pharmaceutical composition according to claim 1, wherein component (b) is ethyl aminobenzoate.

5. 2. The external pharmaceutical composition according to claim 1, wherein component (b) is crotamiton.

6. 2. The pharmaceutical composition for external application according to claim 1, wherein component (b) is benzethonium and / or a salt thereof.

7. 2. The external pharmaceutical composition according to claim 1, wherein the content of (a) minoxidil is 3 to 15 w / v %.

8. The pharmaceutical composition for external application according to any one of claims 1 to 7, further comprising a lower alcohol.

9. The external pharmaceutical composition according to any one of claims 1 to 8, further comprising a polyhydric alcohol.

10. The pharmaceutical composition for external application according to any one of claims 1 to 9, further comprising a pH adjuster.

11. The composition for external use according to claim 8, wherein the lower alcohol is a lower alcohol having 1 to 5 carbon atoms.

12. The external pharmaceutical composition according to claim 9, wherein the polyhydric alcohol is at least one selected from the group consisting of 1,3-butylene glycol, dipropylene glycol, propylene glycol, glycerin, and polyethylene glycol.

13. The pharmaceutical composition for external application according to claim 10, wherein the pH adjuster is at least one selected from the group consisting of citric acid, malic acid, lactic acid, tartaric acid, phosphoric acid, hydrochloric acid, and sulfuric acid.

14. 2. The pharmaceutical composition for external application according to claim 1, wherein the water content is 5 to 75 w / w %.

15. The pharmaceutical composition for external application according to any one of claims 1 to 14, which is in the form of a liquid, a lotion or a tonic.

Citation Information

Patent Citations

  • Combination of pyrimidine derivative, urea and / or allantoin derivative for inducing and stimulating growth of hair to reduce loss thereof

    JP1989287014A

  • Minoxidil-containing pharmaceutical preparation

    JP2001288090A

  • Hair-growing agent

    JP2002029935A

  • Hair tonic composition

    JP2004155690A

  • Compositions and methods for treating alopecia

    US20170042859A1